Print E-mail
Volume 52, Number 4, August 2019

Estimated risk of cardiovascular disease among the HIV-positive patients aged 40 years or older in Taiwan 

Pei-Ying Wu, Mao-Yuan Chen, Wang-Huei Sheng, Szu-Min Hsieh, Yu-Chung Chuang, Aristine Cheng, Sung-Ching Pan, Un-In Wu, Hsi-Yen Chang, Yu-Zhen Luo, Shang-Ping Yang, Jun-Yu Zhang, Hsin-Yun Sun, Chien-Ching Hung


Background and purpose: 

Cardiovascular disease (CVD) is an emerging cause of morbidity and mortality among HIV-positive patients receiving successful combination antiretroviral therapy, but their CVD risk has been rarely investigated in Asia–Pacific region. We aimed to assess the CVD risk of HIV-positive Taiwanese outpatients. 



We did cross-sectional questionnaire interviews to collect information of HIV-positive Taiwanese patients aged 40–79 at the HIV clinics of a medical center from 1 March to 31 August, 2017. The Framingham Risk Score (FRS), Atherosclerotic Cardiovascular Disease (ASCVD) risk score and Data-Collection on Adverse effects of Anti-HIV Drugs (D:A:D) risk score were used to estimate their CVD risk. 



Of the screened 1251 patients, 1006 (80.4%) with complete data to assess their CVD risk were included for analyses. The prevalence of patients aged 40–75 and with a high CVD risk was 30.6% by FRS, 3.7% by D:A:D (R) risk score, and 22.2% by ASCVD risk score. In multiple logistic regression, older age, current smoking, higher systolic blood pressure, and higher triglyceride and fasting glucose levels were independently associated with the ASCVD risk score ≥7.5%. If current smokers aged 55–59 had stopped smoking, the proportions of them with a 10-year CVD risk of ≥10% by FRS and ≥7.5% by ASCVD risk score would have decreased by 35.3% and 20.0%, respectively. 



Higher CVD risk estimates among HIV-positive Taiwanese aged 40–75 were associated with an older age, current smoking, higher systolic blood pressure, hypertriglyceridemia, and hyperglycemia. Smoking cessation could potentially lead to significant decreases of CVD risk. 


Key words:

ComorbidityFramingham equationAtherosclerotic cardiovascular disease (ASCVD)Data-collection on adverse effects of anti-HIV drugs (D:A:D)Antiretroviral therapy